MET amplification in gastric / GEJ adenocarcinoma (~5%): preclinical rationale strong but...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-MET-AMP-GASTRIC |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-GASTRIC |
| Sources | SRC-CIVIC SRC-ESMO-GASTRIC-2024 SRC-NCCN-GASTRIC-2025 |
Actionability Facts
| Biomarker | BIO-MET |
|---|---|
| Variant | amplification (GCN ≥10 or MET/CEP7 ≥4) |
| Disease | DIS-GASTRIC |
| ESCAT tier | IIIA |
| Recommended combinations | clinical trial enrollment (selective MET-TKI basket) |
| Contraindicated monotherapy | rilotumumab (failed RILOMET-1), onartuzumab (failed METGastric) |
| Evidence summary | MET amplification in gastric / GEJ adenocarcinoma (~5%): preclinical rationale strong but phase 3 trials of rilotumumab (anti-HGF; RILOMET-1) and onartuzumab (anti-MET; METGastric) were negative. Selective MET-TKI activity in MET-amp gastric is reported in case series and basket cohorts; no regulatory approval. |
Notes
ESCAT IIIA. OncoKB Level 3B. Standard 1L gastric/GEJ remains fluoropyrimidine + platinum ± trastuzumab (HER2+) ± nivolumab (PD-L1+). MET status is not currently a routine treatment-decision biomarker outside trials.
Used By
No reverse references found in the YAML corpus.